IVMP should be limited to speeding up symptom relief in severe IOI patients

Article

Intravenous methylprednisolone (IVMP) should only be used to increase the rate of symptom relief and recovery from optic nerve dysfunction in patients with severe idiopathic orbital inflammation (IOI).

Intravenous methylprednisolone (IVMP) should only be used to increase the rate of symptom relief and recovery from optic nerve dysfunction in patients with severe idiopathic orbital inflammation (IOI), according to a study published in the British Journal of Ophthalmology.

Dr Ward R. Bijlsma et al., University Medical Center Utrecht, Department of Ophthalmology, The Netherlands, investigated 15 IOI patients treated between 2000 and 2007. A combination of IVMP pulse therapy and oral prednisone (OP) was used to treat 12 IOI patients. They were known as the IVMP+OP group. A further 15 patients only received OP and they were referred to as the OP-only group. The main outcome measures included duration of prednisone treatment, symptom-free outcome and complications.

The results demonstrated that 87% of patients were symptom-free in the OP-only group, compared to 73% in the IVMP+OP group. There were no complications from prednisone therapy.

The IVMP+OP combination was not significantly better at lowering treatment duration, lowering cumulative dose or decreasing persistent symptoms. The study suggests the use of IVMP to treat IOI is better suited to speeding up relief from symptoms and aiding recovery from optic nerve dysfunction.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.